Biosimilars Market Competitive Landscape Company Profiles with Product Details and Competitors and Forecast 2026 | Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer

According to the current analysis of Reports and Data, the global Biosimilars Market was valued at USD 5.10 Billion in 2018 and is expected to reach USD 44.56 Billion by year 2026, at a CAGR of 30.8%. Biosimilar are alternatives to existing patented, and approved biologicss and possess similar medicinal properties as compared to the original biologics. The biosimilars vary a little from original biologics in terms of structure but must have similar safety and efficacy as compared to the originator biologics. Biosimilars development does not require Phase II clinical trial for approval and the focus is put on determination of 'biosimilarity' to the reference originator biologics. Thus it has much reduced clinical development timelines and reduced product costs as compared to use of original biologics.

To look at the PDF Sample Report and get 30 minutes of a free consultation @ https://www.reportsanddata.com/sample-enquiry-form/1177

Key participants include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Samsung Biologics, Sandoz, Stada Arzneimittel, and Teva Pahrmaceutical .

For the purpose of this report, Reports and Data has segmented the Biosimilars market on the basis of type, disease type, and region:

Type (Revenue, USD Million; 2016-2026)
o Recombinant Non-glycosylated Proteins
o Insulin
o Recombinant Human Growth Hormone
o Granulocyte Colony-stimulating Factor
? Filgrastim
? Pegfilgrastim
o Interferons
? Interferon-Beta
? Interferon-Alpha
o Recombinant Glycosylated Proteins
? Erythropoietin
? Monoclonal Antibodies
? Adalimumab
? Bevacizumab
? Infliximab
? Rituximab
? Trastuzumab
? Other Monoclonal Antibodies
? Follitropin
? Etanercept
o Recombinant Peptides
? Glucagon
? Calcitonin

Disease Type (Revenue, USD Million; 2016-2026)
o Oncology
o Blood Disorders
o Chronic Diseases
o Autoimmune Diseases
o Growth Hormone Deficiency
o Infectious Diseases
o Other Diseases

Regional Outlook (Revenue in USD Million; 2016-2026)
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)

To avail this report at great discount rates, click here @ https://www.reportsanddata.com/discount-enquiry-form/1177

The global market is driven by various of factors such as global prevalence of target disease prevalence across the globe, launch of biosimilars by various market players, favorable investments scenario, and upcoming patent expiry.

The Biosimilars market is characterized by presence of significant number of pharmaceutical giants as well as emerging players operating across the globe. Additionally, availability of research fundings, demand for cheaper biologics alternative and favorable regulatory scenario in Europe and Asia pacific is propelling the market in these regions. However, some regions such as U.S are facing slow adoption of biosimilars with first biosimilar approved in 2015 for Sandoz's Zarxio (filgrastim), and 3, 5, and 7, biosimilars approved by FDA in 2016, 2017, and 2018, respectively..

Further key findings from the report suggest
o Biosimilars market is growing at a CAGR of 2% in Asia Pacific followed by North America and Europe, with 21.0% and 31.4% CAGR, respectively. High chronic disease prevalence across the globe is the key factor to accelerate the market growth during forecast period across all regions.
o As of 2018, Recombinant Non-glycosylated Proteins is the dominating Biosimilars which holds over 60% of the global market. European regional market is the chief revenue generating source for this product segment, followed by North America and Asia-Pacific regions.
o Recombinant Glycosylated Proteins is expected to be the fastest growing market segment during forecast period 2019-2026 with a CAGR of 33.4%. However, regulatory obstacles and manufacturing complexity are major challenge for the market growth of this market segment.
o Recombinant Peptides segment was estimated to account for USD 501.00 million in 2018 and is expected to grow reach USD 4.38 Billion by year 2026.
o Asia Pacific is expected to account for the 32.8% of the global Biosimilars market. Developing nations such China, and India are likely to witness high growth.
o Some regions such as U.S. and Latin America are facing slow adoption of biosimilars due to stringent regulatory framework..

Table of Content

Global Biosimilars Market Research Report

Chapter 1 Global Biosimilars Market Overview
Chapter 2 Global Economic Impact on Industry
Chapter 3 Global Market Competition by Manufacturers
Chapter 4 Global Productions, Revenue (Value) by Region
Chapter 5 Global Supplies (Production), Consumption, Export, Import by Regions
Chapter 6 Global Productions, Revenue (Value), Price Trend by Type
Chapter 7 Global Market Analysis by Application
Chapter 8 Manufacturing Cost Analysis
Chapter 9 Industrial Chain, Sourcing Strategy, and Downstream Buyers
Chapter 10 Marketing Strategy Analysis, Distributors/Traders
Chapter 11 Market Effect Factors Analysis
Chapter 12 Global Biosimilars Market Forecast

To read the full report now, with industry-wide coverage, visit:
https://www.reportsanddata.com/report-detail/global-biosimilars-market

Thanks for reading this article; you can also customize this report to get select chapters or region-wise coverage with regions like Asia, United States, Europe, etc.

Contact Us:

John Watson
Head of Business Development
40 Wall St. 28th floor New York City, NY 10005 United States
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com

About Us:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

This release was published on openPR.